The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a statement following the publication of a meta-analysis in the New England Journal of Medicine linking rosiglitazone with cardiovascular events.
The MHRA have highlighted that the product information for rosiglitazone has carried warnings about heart failure since 2000 and myocardial infarction since 2006.
The MHRA advice is that "patients should not stop treatment with rosiglitazone but should discuss their medication with their doctor at their next routine appointment".
Action: Clinicians should be aware of the MHRA advice and discuss alternative treatment options with patients currently taking rosiglitazone at their next routine appointment.
|« May NICE Guidance||Decision Aids may improve compliance »|